Sarepta Exercises Option to Acquire Myonexus Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sarepta Therapeutics (SRPT) PT Raised to $213 at Cowen
February 28, 2019 6:21 AM ESTCowen analyst Ritu Baral raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $213.00 (from $178.00) while maintaining a Outperform rating.
Baral commented, "SRPT reported 4Q18 with pre-announced Exondys revenues only slightly below consensus but meeting FY18 guidance. SRPT provided timeline updates for its... More
Sarepta (SRPT) Phase I/IIa MYO-101 Trial Data 'Striking' - SunTrust
February 27, 2019 11:55 AM ESTSunTrust analyst Edward Nash reiterated a Buy rating and $176 price target on Sarepta Therapeutics (NASDAQ: SRPT) following 'striking' preliminary results from a Phase I/IIa MYO-101 study in Limb-Girdle Muscular Dystrophy Type 2E (LGMD2E) or beta-sarcoglycanopathy, a severe and debilitating form of LGMD characterized by progressive muscle fiber loss,... More
Sarepta Therapeutics (SRPT) Hits Pre-market High, Up 7% with Conference Call Onoing
February 27, 2019 8:16 AM ESTSarepta Therapeutics (NASDAQ: SRPT) Hits Pre-market High, Up 7% with Conference Call Onoing
